Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 20.05.2024 3 Am J Hematol 4 Ann Hematol 6 Blood 1 BMC Cancer 1 Bone Marrow Transplant 9 Br J Haematol 1 Cancer 1 Exp Hematol 1 Genes Chromosomes Cancer 2 Int J Hematol 2 J Clin Oncol 2 J Pediatr Hematol Oncol 3 Leuk Lymphoma 6 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
   Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
   Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367.
   PubMed        
   
   
2. BEWERSDORF JP, Shimony S, Shallis RM, Liu Y, et al
   Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
   Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366.
   PubMed        
   
   
3. CLAUDIANI S, Chee L, Fernando F, Brown L, et al
   Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
   Am J Hematol. 2024;99:1172-1174.
   PubMed         Abstract available
   
   

   
   Ann Hematol

4. CUI T, Li H, Zhou S, Li J, et al
   Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
   Ann Hematol. 2024 May 17. doi: 10.1007/s00277-024-05791.
   PubMed         Abstract available
   
   
5. FONTECHA MB, Anadon MDR, Mercado Guzman V, Stanganelli C, et al
   Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
   Ann Hematol. 2024 May 14. doi: 10.1007/s00277-024-05794.
   PubMed         Abstract available
   
   
6. TOLLE M, Gokbuget N, Habringer S, Keller U, et al
   Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
   Ann Hematol. 2024 May 11. doi: 10.1007/s00277-024-05789.
   PubMed        
   
   
7. JAIN AG, Gesiotto Q, Ball S, Nodzon L, et al
   Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
   Ann Hematol. 2024;103:1941-1945.
   PubMed         Abstract available
   
   

   
   Blood

8. FISKUS W, Piel J, Collins MP, Hentemann M, et al
   BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
   Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
   PubMed         Abstract available
   
   
9. WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al
   Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
   Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659.
   PubMed         Abstract available
   
   
10. 
    MRD and EFS in pediatric T-lymphoblastic lymphoma.
    Blood. 2024;143:2111.
    PubMed        
    
    
11. 
    Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
    Blood. 2024;143:2108-2110.
    PubMed        
    
    
12. RIBERA JM
    MRD: also for T-lymphoblastic lymphoma.
    Blood. 2024;143:2017-2019.
    PubMed        
    
    
13. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
    MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
    Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. ALSHEMMARI SH, AlSarraf A, Kaempf A, Danilov AV, et al
    Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort.
    BMC Cancer. 2024;24:584.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

15. MORA E, Montoro J, Balaguer A, Rovira M, et al
    Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298.
    PubMed         Abstract available
    
    

    
    Br J Haematol

16. LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
    Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
    Br J Haematol. 2024;204:1732-1739.
    PubMed         Abstract available
    
    
17. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    PubMed         Abstract available
    
    
18. BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
    HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
    Br J Haematol. 2024;204:1920-1934.
    PubMed         Abstract available
    
    
19. JO T, Ueda T, Akahoshi Y, Kondo T, et al
    First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1913-1919.
    PubMed         Abstract available
    
    
20. LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
    Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Br J Haematol. 2024;204:1872-1881.
    PubMed         Abstract available
    
    
21. KRIEGER E, Qayyum R, Toor A
    Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
    Br J Haematol. 2024;204:1935-1943.
    PubMed         Abstract available
    
    
22. MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
    Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1687-1696.
    PubMed         Abstract available
    
    
23. ZHANG X, Tao C, Long F
    Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
    Br J Haematol. 2024;204:1569-1570.
    PubMed        
    
    
24. BALDUZZI A
    The CAR T-cell race: The rules of the game.
    Br J Haematol. 2024;204:1579-1581.
    PubMed         Abstract available
    
    

    
    Cancer

25. BAZARBACHI AH, Labopin M, Raiola AM, Blaise D, et al
    Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Tran
    Cancer. 2024 May 17. doi: 10.1002/cncr.35365.
    PubMed         Abstract available
    
    

    
    Exp Hematol

26. ZHOU Q, Li Z, Xi Y
    EV-mediated intercellular communication in acute myeloid leukemia: Transport of genetic materials in the bone marrow microenvironment.
    Exp Hematol. 2024;133:104175.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

27. RAGNARSSON C, Yang M, Moura-Castro LH, Aydin E, et al
    Constitutional and acquired genetic variants in ARID5B in pediatric B-cell precursor acute lymphoblastic leukemia.
    Genes Chromosomes Cancer. 2024;63:e23242.
    PubMed         Abstract available
    
    

    
    Int J Hematol

28. SHI X, Feng M, Nakada D
    Metabolic dependencies of acute myeloid leukemia stem cells.
    Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03789.
    PubMed         Abstract available
    
    
29. AKIYAMA H, Kantarjian H, Jabbour E, Issa G, et al
    Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
    Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03787.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

30. DAVER NG, Craddock C
    Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome.
    J Clin Oncol. 2024;42:1731-1733.
    PubMed        
    
    
31. WANG ES, Goldberg AD, Tallman M, Walter RB, et al
    Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1776-1787.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

32. TORET E, Aytac S, Guzelkucuk Z, Celkan T, et al
    Prognosis of Second Primary Malignancies in Pediatric Acute Lymphoblastic Leukemia Survivors: A Multicenter Study by the Turkish Pediatric Hematology Society.
    J Pediatr Hematol Oncol. 2024 May 16. doi: 10.1097/MPH.0000000000002881.
    PubMed         Abstract available
    
    
33. ZHU G, Xiang L, Liu J
    Regarding the Biochemical and Hematologic Profiles in B-Cell Acute Lymphoblastic Leukemia Children.
    J Pediatr Hematol Oncol. 2024 May 14. doi: 10.1097/MPH.0000000000002878.
    PubMed        
    
    

    
    Leuk Lymphoma

34. MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al
    Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700.
    PubMed         Abstract available
    
    
35. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    PubMed        
    
    
36. WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al
    A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577.
    PubMed         Abstract available
    
    

    
    Leukemia

37. CORTES JE, Sasaki K, Kim DW, Hughes TP, et al
    Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278.
    PubMed         Abstract available
    
    
38. MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267.
    PubMed         Abstract available
    
    
39. NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al
    Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
    Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264.
    PubMed         Abstract available
    
    
40. KARAMI A, Skorski T
    DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269.
    PubMed        
    
    
41. AWADA H, Durmaz A, Kewan T, Ullah F, et al
    Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268.
    PubMed        
    
    
42. MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al
    TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276.
    PubMed         Abstract available
    
    

    
    PLoS One

43. SUZUKI S, Suzuki S, Sato-Nagaoka Y, Ito C, et al
    Identification of triciribine as a novel myeloid cell differentiation inducer.
    PLoS One. 2024;19:e0303428.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.